Curatis Holding AG to Present at Investora and Release H1 Report Early

On September 12, 2024, Curatis Holding AG (SIX:CURN), a pharma company specializing in orphan drugs, announced its first participation at the Investora conference. The company will present its business model on September 19 at 8:00 AM. Consequently, it will release its half-year report on September 16 rather than later in the month.

The Investora conference is a key event for investors in Swiss stocks. Curatis’ top executives, including Dr. Roland Rutschmann (CEO), Patrick Ramsauer (CFO), and Günter Graubach (CCDO and founder), will be present to address investor inquiries.

Curatis is making progress with its lead project C-PTBE-01, which has been submitted for Orphan Drug Designation to the FDA. The company is preparing for a pivotal study meeting with the FDA, planned for Q4 2025.